Asparagine synthetase (ASNS) Drives Tumorigenicity in Small Cell Lung Cancer
Open Access
- 15 December 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 3087
Abstract
Objectives: Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma characterized by rapid proliferation, early metastasis, and limited therapeutic response. Metabolic reprogramming is increasingly recognized as a key feature of small cell lung cancer progression, yet the contribution of specific metabolic enzymes remains incompletely understood. This study aimed to investigate the role of asparagine synthetase in small cell lung cancer tumorigenicity and disease progression. Methods: Integrative analyses were performed using public transcriptomic datasets, proteomic profiling, and functional assays in vitro and in vivo. Asparagine synthetase expression levels were evaluated in normal lung, non-small cell lung cancer, and small cell lung cancer tissues using public microarray datasets. Loss of function studies were conducted using shRNA mediated knockdown in murine and human small cell lung cancer cell models. Tumor growth and survival were assessed using xenograft mouse models. Results: Asparagine synthetase expression was significantly elevated in small cell lung cancer compared with normal lung and non-small cell lung cancer tissues. Genetic depletion of asparagine synthetase impaired cellular proliferation and colony forming capacity in vitro. In vivo, asparagine synthetase knockdown suppressed tumor growth and was associated with prolonged survival in xenograft mouse models. Conclusions: These findings demonstrate that asparagine synthetase contributes to tumor growth and metabolic adaptability in small cell lung cancer. The results support a functional role for asparagine synthetase in malignant progression and suggest that targeting asparagine metabolism may represent a potential therapeutic approach in aggressive small cell lung cancer.Keywords
Funding Information
- Korea government (RS-2024-00335760)
- Korea government (NRF-2021R1C1C1004165)
- Ministry of Education (RS-2023-00301914)
- Ministry of Education (RS-2024-00445180)
This publication has 60 references indexed in Scilit:
- Patient‐derived xenograft models in pan‐cancer: From bench to clinicInterdisciplinary Medicine, 2025
- Cemented versus cementless Oxford unicompartmental knee arthroplasty for the treatment of medial knee osteoarthritis: an updated systematic review and meta-analysisArchives of orthopaedic and trauma surgery, 2024
- Bisabosqual A: A novel asparagine synthetase inhibitor suppressing the proliferation and migration of human non-small cell lung cancer A549 cellsEuropean Journal of Pharmacology, 2023
- Metabolic reprogramming in cancer: Mechanisms and therapeuticsMedcomm, 2023
- Expert consensus on treatment for stage III non‐small cell lung cancerMedicine Advances, 2023
- Targeting extracellular nutrient dependencies of cancer cellsMolecular Metabolism, 2020
- As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino AcidCell Metabolism, 2018
- The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA TransferCell, 2018
- Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-AsparaginaseCancer Cell, 2018
- Deficiency of Asparagine Synthetase Causes Congenital Microcephaly and a Progressive Form of EncephalopathyNeuron, 2013